Therapeutic antibodies for COVID-19
Eli Lilly and Company received foundation support to facilitate access to future Lilly therapeutic antibodies under development for the prevention and treatment of COVID-19 in low- and middle-income countries as part of the COVID-19 Therapeutics Accelerator. The antibodies will be manufactured at FUJIFILM Diosynth Biotechnologies facility in Denmark.
-
Domain
-
Investment typeVolume guarantee
-
StatusExit
-
Initial investmentPublic
-
Partnered in2020
-
Investment leadRyan Kreitzer
-
HeadquartersUSA
-
Program strategyCOVID-19 Response
More about our work
Our focus
Our six domains of focus comprise 40+ program strategies across the Foundation’s nearly $9B annual charitable support.
Investment approach
Fostering partnerships with the private sector to leverage groundbreaking global innovations for societal good.
Our team
We bring depth of experience to every investment, with a proven track record across sectors and scale.